Peninsula Asset Management Inc. Purchases 2,839 Shares of Stryker Corporation $SYK

Peninsula Asset Management Inc. increased its position in Stryker Corporation (NYSE:SYK) by 15.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,817 shares of the medical technology company’s stock after purchasing an additional 2,839 shares during the period. Stryker makes up 3.5% of Peninsula Asset Management Inc.’s investment portfolio, making the stock its 9th largest holding. Peninsula Asset Management Inc.’s holdings in Stryker were worth $6,840,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of SYK. Czech National Bank boosted its position in shares of Stryker by 3.9% during the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after buying an additional 3,366 shares during the last quarter. Daymark Wealth Partners LLC raised its position in Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after buying an additional 37,307 shares during the last quarter. Varma Mutual Pension Insurance Co raised its position in Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after buying an additional 5,100 shares during the last quarter. Wealthcare Advisory Partners LLC lifted its stake in Stryker by 265.2% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock valued at $3,278,000 after acquiring an additional 6,774 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new position in Stryker during the 3rd quarter valued at $17,547,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last three months. Company insiders own 4.60% of the company’s stock.

Stryker Trading Up 1.7%

NYSE SYK opened at $316.46 on Thursday. The stock has a market capitalization of $121.32 billion, a price-to-earnings ratio of 36.63, a PEG ratio of 1.99 and a beta of 0.77. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The business’s fifty day moving average is $311.28 and its 200-day moving average is $337.10.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the previous year, the company posted $2.84 EPS. Stryker’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.

Analysts Set New Price Targets

Several analysts have recently issued reports on SYK shares. Barclays reduced their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Evercore set a $350.00 price target on shares of Stryker in a report on Monday, July 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on shares of Stryker in a research note on Friday, May 1st. Finally, Needham & Company LLC dropped their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $392.52.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.